Interius is a preclinical stage company expanding the potential of gene therapy by reengineering viral vectors to drive cell-specific therapy.
Location: United States, Pennsylvania, Philadelphia
Phone: +52 958 117 1026
Total raised: $76M
Investors 7
Funding Rounds 1
| Date | Series | Amount | Investors |
| 19.05.2021 | Series A | $76M | - |
Mentions in press and media 7
| Date | Title | Description |
| 09.07.2024 | Interius BioTherapeutics Receives HREC Approval and CTN Clearance from the TGA to Commence a Phase 1 Clinical Trial for Its First-in-Class In Vivo CAR Therapeutic for B Cell Malignancies | Will initiate a first-in-human Phase 1 clinical trial for INT2104, its first-in-class in vivo targeted gene therapy, creating CAR cells for the treatment of B cell malignancies in 4Q24 PHILADELPHIA, July 9, 2024 /PRNewswire/ -- Interius Bio... |
| 18.05.2021 | Interius BioTherapeutics Raises $76M in Series A Financing | Interius BioTherapeutics, a Philadelphia, PA-based preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery, raised $76m in Series A financing. The round was co-led by Cormorant ... |
| 18.05.2021 | Interius BioTherapeutics Raises $76M Series A Financing to Advance Breakthrough Cell and Gene Therapy Platform | |
| 27.07.2012 | Fundraising: Gene therapy firm targeting sickle cell anemia raises $60M | Product: Gene therapy to target sickle cell anemia, beta-thalassemia and childhood cerebral adrenoleukodystrophy Money raised: $60 million in series D; at least $76 million in previous rounds based on press releases and U.S. Securities and ... |
| - | Interius BioTherapeutics | “Interius is a preclinical stage company expanding the potential of gene therapy by reengineering viral vectors to drive cell-specific therapy.” |
| - | Interius BioTherapeutics Raises $76M Series A Financing to Advance Breakthrough Cell and Gene Therapy Platform | PHILADELPHIA, May 18, 2021 /PRNewswire/ -- Interius BioTherapeutics, a preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery, today announced that it has raised $76 million in... |
| - | Fundraising: Gene therapy firm targeting sickle cell anemia raises $60M | Company name: bluebird bio. Industry: Biotechnology. Location: Cambridge, Massachusetts. Product: Gene therapy to target sickle cell anemia, beta-thalassemia and childhood cerebral adrenoleukodystrophy Money raised: $60 million in series D;... |